Open AccessAntihypertensive and cerebroprotective effects of Egiloc retard in hypertensive patients with chronic hypertensive encephalopathy
Author(s) -
N. L. Afanasieva,
А. М. Русина,
V. Mordovin
Publication year - 2009
Publication title -
arterialʹnaâ gipertenziâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 5
eISSN - 2411-8524
pISSN - 1607-419X
DOI - 10.18705/1607-419x-2009-15-1-50-56
Subject(s) - metoprolol , medicine , blood pressure , ambulatory blood pressure , ambulatory , essential hypertension , encephalopathy , retard , concomitant , anesthesia , cardiology , psychiatry
Aim. The study addresses antihypertensive and cerebroprotective effects of long acting metoprolol (Egiloc retard, Egis, Hungary). Materials and methods. 47 objects with I-II stages of hypertension without serious concomitant diseases (25 males and 22 females, average age 51,7 ± 10,6 years) were included. Long acting metoprolol was administered (Egiloc retard, Egis, Hungary) in a dose of 25-100 mg given 1-2 times per day. 24-hour ambulatory blood pressure monitoring (ABPM), magnetic resonance tomography and dynamic contrast-enhanced perfusion computer scan of the brain with brain blood flow estimation were performed in all patients initially and after 6-month-therapy. Results. Egiloc retard showed a significant antihypertensive effect according to office and ABPM blood pressure. Egiloc retard normalizes 24-hour blood pressure profile in over-dippers and night-peakers. Subjective amelioration and improvement of functional and structural changes were found in hypertensive patients after 6-month therapy by Egiloc retard. Good tolerance and no significant abnormal changes of glucose and lipid metabolism were observed in patients taking Egiloc retard. It is also shown that Egiloc retard has the cerebroprotective effects.